Skip to content Home / Companies / XENE XEN
Xenon Pharmaceuticals Inc. (XENE) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest XENE Insider Trades
About Xenon Pharmaceuticals Inc. (XENE) Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Headquarters BURNABY
Employees 370
Listed 2014
Exchange XNAS https://www.xenon-pharma.com SEC filings for XENE on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 3 12,512 $774K Grant or award 14 84,700 Option exercise 14 37,030
XENE Insider Transactions (Form 4) 112 29 Form 4 filings on record, the earliest from Nov 22, 2024, newest first.
Date Insider Transaction Security Shares Price Value Aug 11, 2026 SG Steven Gannon - Director Open-market sale Common Shares
Recent XENE Form 8-K Filings 5
Recent XENE Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 28, 2026 CHRISTOPHER KENNEY Officer 7,068 $438K View on EDGAR Aug 13, 2026 STEVEN GANNON Director
XENE Insider Trading - FAQ
What is the latest insider trade for XENE? Xenon Pharmaceuticals Inc. (XENE) had 10 insider filings in the last 90 days, with the most recent on 2026-08-13. The full record for XENE runs to 29 Form 4 filings, the earliest from 2024-11-22. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying XENE stock? No insider purchases of XENE were filed in the last 90 days.
How many insiders are selling XENE stock? 3 insider sales of XENE were filed in the last 90 days, totaling $774K.
Where can I see XENE SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks XENE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow XENE insider buys? Create a free InsiderAlpha account and press Watch on this page to add XENE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track XENE insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free
Market cap $5.81B
P/E ratio -
Dividend yield -
Average volume 1.25M
52 week high $72.66
52 week low $35.60
Today's high $61.62
Today's low $59.81
Open $61.31
Volume 587.9K
Previous close $61.93
Shares outstanding 96.84M Market cap
$5.81B
370 employees
XENE Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 3 sales totaling $774K.
Most-Active XENE Insiders - Last 90 Days 10 Tax withholding / forfeiture 2 2,832
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Jun 5, 2026 GP Gary Patou Open-market sale Common Shares 1,322 $53.14 $70K
Jun 5, 2026 GC Gillian Cannon Open-market sale Common Shares 1,190 $53.14 $63K
Jun 1, 2026 GP Gary Patou Option exercise Common Shares 2,645 - -
Jun 1, 2026 GP Gary Patou Option exercise Restricted Share Units 2,645 $0.00 -
Jun 3, 2026 GP Gary Patou Grant or award Share Option (Right to Buy) 10,507 $0.00 -
Jun 3, 2026 GP Gary Patou Grant or award Restricted Share Units 1,593 $0.00 -
Jun 1, 2026 PM Patrick Machado Option exercise Restricted Share Units 2,645 $0.00 -
Jun 3, 2026 PM Patrick Machado Grant or award Share Option (Right to Buy) 10,507 $0.00 -
Jun 3, 2026 PM Patrick Machado Grant or award Restricted Share Units 1,593 $0.00 -
Jun 1, 2026 JG Justin D. Gover Option exercise Restricted Share Units 2,645 $0.00 -
Jun 3, 2026 JG Justin D. Gover Grant or award Share Option (Right to Buy) 10,507 $0.00 -
Jun 3, 2026 JG Justin D. Gover Grant or award Restricted Share Units 1,593 $0.00 -
Jun 1, 2026 SG Steven Gannon Tax withholding / forfeiture Common Shares 1,416 $53.41 $76K
Jun 1, 2026 SG Steven Gannon Option exercise Restricted Share Units 2,645 $0.00 -
Jun 3, 2026 SG Steven Gannon Grant or award Share Option (Right to Buy) 10,507 $0.00 -
Jun 3, 2026 SG Steven Gannon Grant or award Restricted Share Units 1,593 $0.00 -
Jun 1, 2026 GC Gillian Cannon Option exercise Restricted Share Units 2,645 $0.00 -
Jun 3, 2026 GC Gillian Cannon Grant or award Share Option (Right to Buy) 10,507 $0.00 -
Jun 3, 2026 GC Gillian Cannon Grant or award Restricted Share Units 1,593 $0.00 -
Jun 1, 2026 DS Dawn Svoronos Tax withholding / forfeiture Common Shares 1,416 $53.41 $76K
Jun 1, 2026 DS Dawn Svoronos Option exercise Restricted Share Units 2,645 $0.00 -
Jun 3, 2026 DS Dawn Svoronos Grant or award Share Option (Right to Buy) 10,507 $0.00 -
Jun 3, 2026 DS Dawn Svoronos Grant or award Restricted Share Units 1,593 $0.00 -
May 12, 2026 SG Steven Gannon Option exercise Common Shares 3,500 $7.38 $26K
May 12, 2026 SG Steven Gannon Option exercise Stock Option (Right to Buy) 3,500 $0.00 -
Mar 12, 2026 AD Andrea Difabio - Officer Option exercise Common Shares 3,750 - -
Mar 13, 2026 AD Andrea Difabio - Officer Open-market sale Common Shares 1,342 $55.23 $74K
Mar 12, 2026 AD Andrea Difabio - Officer Option exercise Restricted Share Units 3,750 $0.00 -
Mar 12, 2026 IM Ian Mortimer - Officer Option exercise Common Shares 12,500 - -
Mar 13, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 7,308 $55.23 $404K
Mar 12, 2026 IM Ian Mortimer - Officer Option exercise Restricted Share Units 12,500 $0.00 -
Mar 9, 2026 AD Andrea Difabio - Officer Option exercise Common Shares 7,500 - -
Mar 10, 2026 AD Andrea Difabio - Officer Open-market sale Common Shares 2,607 $60.11 $157K
Mar 9, 2026 AD Andrea Difabio - Officer Grant or award Performance Share Units 7,500 $0.00 -
Mar 9, 2026 AD Andrea Difabio - Officer Option exercise Performance Share Units 7,500 $0.00 -
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 12,479 $59.50 $743K
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 10,072 $60.47 $609K
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 2,449 $61.26 $150K
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 65,000 $62.06 $4.03M
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Common Shares 20,000 - -
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Stock Option 75,000 $0.00 -
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Stock Option 25,000 $0.00 -
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Stock Option 105,000 $0.00 -
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Stock Option 65,000 $0.00 -
Mar 9, 2026 IM Ian Mortimer - Officer Grant or award Performance Share Units 20,000 $0.00 -
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Performance Share Units 20,000 $0.00 -
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Common Shares 75,000 $8.40 $630K
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Common Shares 25,000 $3.10 $78K
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Common Shares 105,000 $4.75 $499K
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 21,791 $58.81 $1.28M
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 31,694 $59.88 $1.90M
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 21,515 $60.49 $1.30M
Mar 9, 2026 IM Ian Mortimer - Officer Option exercise Common Shares 65,000 $9.44 $614K
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 43,348 $59.26 $2.57M
Mar 9, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 61,652 $60.08 $3.70M
Mar 10, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 11,269 $60.11 $677K
Jan 9, 2026 DC Darren S. Cline - Officer Grant or award Share Option (Right to Buy) 40,000 $0.00 -
Jan 9, 2026 DC Darren S. Cline - Officer Grant or award Restricted Share Units 20,000 $0.00 -
Jan 9, 2026 AD Andrea Difabio - Officer Grant or award Share Option (Right to Buy) 80,000 $0.00 -
Jan 9, 2026 AD Andrea Difabio - Officer Grant or award Restricted Share Units 15,000 $0.00 -
Jan 9, 2026 IM Ian Mortimer - Officer Grant or award Share Option (Right to Buy) 350,000 $0.00 -
Jan 9, 2026 IM Ian Mortimer - Officer Grant or award Restricted Share Units 65,000 $0.00 -
Jan 2, 2026 IM Ian Mortimer - Officer Option exercise Common Shares 40,000 $7.49 $300K
Jan 2, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 37,938 $44.40 $1.68M
Jan 2, 2026 IM Ian Mortimer - Officer Open-market sale Common Shares 2,062 $44.93 $93K
Jan 2, 2026 IM Ian Mortimer - Officer Option exercise Stock Option (Right to Buy) 40,000 $0.00 -
Dec 5, 2025 IM Ian Mortimer - Officer Open-market sale Common Shares 14,375 $45.03 $647K
Dec 8, 2025 IM Ian Mortimer - Officer Open-market sale Common Shares 8,820 $45.59 $402K
Dec 8, 2025 IM Ian Mortimer - Officer Open-market sale Common Shares 2,010 $46.32 $93K
Nov 28, 2025 IM Ian Mortimer - Officer Open-market sale Common Shares 97 $45.01 $4K
Oct 1, 2025 IM Ian Mortimer - Officer Option exercise Common Shares 25,000 $7.69 $192K
Oct 1, 2025 IM Ian Mortimer - Officer Open-market sale Common Shares 25,000 $40.16 $1.00M
Oct 1, 2025 IM Ian Mortimer - Officer Option exercise Stock Option (Right to Buy) 25,000 $0.00 -
Jun 5, 2025 GP Gary Patou Grant or award Share Option (Right to Buy) 17,012 $0.00 -
Jun 5, 2025 GP Gary Patou Grant or award Restricted Share Units 2,645 $0.00 -
Dec 18, 2024 SA Sherry Aulin - Officer Option exercise Common Shares 9,334 $9.44 $88K
Dec 18, 2024 SA Sherry Aulin - Officer Tax withholding / forfeiture Common Shares 2,135 $41.28 $88K
Dec 18, 2024 SA Sherry Aulin - Officer Open-market sale Common Shares 7,199 $41.23 $297K
Dec 18, 2024 SA Sherry Aulin - Officer Option exercise Common Shares 16,000 $11.58 $185K
Dec 18, 2024 SA Sherry Aulin - Officer Tax withholding / forfeiture Common Shares 4,490 $41.28 $185K
Dec 18, 2024 SA Sherry Aulin - Officer Open-market sale Common Shares 11,510 $41.19 $474K
Dec 18, 2024 SA Sherry Aulin - Officer Option exercise Stock Option (Right to Buy) 9,334 $0.00 -
Dec 18, 2024 SA Sherry Aulin - Officer Option exercise Stock Option (Right to Buy) 16,000 $0.00 -
Nov 22, 2024 GP Gary Patou Option exercise Common Shares 3,500 $7.38 $26K
Nov 22, 2024 GP Gary Patou Tax withholding / forfeiture Common Shares 649 $39.80 $26K
Nov 22, 2024 GP Gary Patou Open-market sale Common Shares 2,851 $41.11 $117K
Nov 22, 2024 GP Gary Patou Option exercise Common Shares 3,086 $13.48 $42K
Nov 22, 2024 GP Gary Patou Tax withholding / forfeiture Common Shares 1,046 $39.80 $42K
Nov 22, 2024 GP Gary Patou Open-market sale Common Shares 2,040 $41.05 $84K
Nov 22, 2024 GP Gary Patou Option exercise Stock Option (Right to Buy) 3,500 $0.00 -
Nov 22, 2024 GP Gary Patou Option exercise Stock Option (Right to Buy) 3,086 $0.00 -
$YARW
Yarrow Bioscience, Inc.
$IONS
IONIS PHARMACEUTICALS INC
Steven Gannon - DirectorOpen-market sale$641K
